Targeted Therapies for Hepatocellular Carcinoma
TLDR
Identification of oncogenes that mediate tumor progression, and trials that monitor their products as biomarkers, might lead to personalized therapy; reagents that interfere with signaling pathways required for HCC progression might be used to treat selected populations, and thereby maximize the efficacy and cost benefit.About:
This article is published in Gastroenterology.The article was published on 2011-05-01 and is currently open access. It has received 402 citations till now. The article focuses on the topics: Sorafenib & Targeted therapy.read more
Citations
More filters
Journal ArticleDOI
EASL-EORTC clinical practice guidelines : management of hepatocellular carcinoma
Peter R. Galle,Alejandro Forner,Josep M. Llovet,Vincenzo Mazzaferro,Fabio Piscaglia,Jean-Luc Raoul,Peter Schirmacher,Valérie Vilgrain +7 more
TL;DR: The following Clinical Practice Guidelines will give up-to-date advice for the clinical management of patients with hepatocellular carcinoma, as well as providing an in-depth review of all the relevant data leading to the conclusions herein.
EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver ⇑ , European Organisation for Research and Treatment of Cancer
Josep M. Llovet,Michel Ducreux,Riccardo Lencioni,Adrian M. Di Bisceglie,Jean-Francois J. DuFour,Tim F. Greten,Eric Raymond,Tania Roskams,Vincenzo Mazzaferro,Jordi Bruix,Massimo Colombo,Andrew X. Zhu +11 more
TL;DR: The purpose of this document is to assist physicians, patients, health-care providers, and health-policy makers from Europe and worldwide in the decision-making process according to evidencebased data.
Journal ArticleDOI
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.
Bruno Sangro,Carlos Gomez-Martin,Manuel de la Mata,Mercedes Iñarrairaegui,Elena Garralda,Pilar Barrera,Jose I Riezu-Boj,Esther Larrea,Carlos Alfaro,Pablo Sarobe,Juan José Lasarte,Jose Luis Perez-Gracia,Ignacio Melero,Ignacio Melero,Jesús Prieto,Jesús Prieto +15 more
TL;DR: Tremelimumab safety profile and antitumor and antiviral activity, in patients with advanced HCC developed on HCV-induced liver cirrhosis, support further investigation.
Journal ArticleDOI
Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma
TL;DR: In this paper, a review outlines pathogenic mechanisms that seem to be common to both hepatitis B virus and hepatitis C virus and suggest innovative approaches to the prevention and treatment of HCC.
Journal ArticleDOI
Mechanisms of HBV-induced hepatocellular carcinoma
TL;DR: HBV-related HCCs may arise on non-cirrhotic livers, further supporting the notion that HBV plays a direct role in liver transformation by triggering both common and etiology specific oncogenic pathways in addition to stimulating the host immune response and driving liver chronic necro-inflammation.
References
More filters
Journal ArticleDOI
Molecular Basis of Colorectal Cancer
TL;DR: This review gives an account of recent advances in the authors' knowledge of the molecular mechanisms in colorectal cancer.
Journal ArticleDOI
Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group.
Mei-Hwei Chang,Chien-Jen Chen,Mei-Shu Lai,Hsu-Mei Hsu,Tzee-Chung Wu,Man-Shan Kong,Der-Cherng Liang,Wen-Yi Shau,Ding-Shinn Chen +8 more
TL;DR: The incidence of hepatocellular carcinoma in children in Taiwan from 1981 to 1994 has declined since the institution of Taiwan's program of universal hepatitis B vaccination, and the corresponding rates of mortality have decreased.
Journal ArticleDOI
Addiction to Oncogenes—the Achilles Heal of Cancer
TL;DR: Weinstein et al. as mentioned in this paper showed that even brief inactivation of an oncogene can permanently reverse the malignant phenotype of some types of tumor, which is a promising result.
Journal ArticleDOI
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
TL;DR: Evidence is presented for a large class of non-oncogenes that are essential for cancer cell survival and present attractive drug targets and theoretical considerations for combining orthogonal cancer therapies are provided.
Journal ArticleDOI
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis
Vincenzo Mazzaferro,Josep M. Llovet,Rosalba Miceli,Sherrie Bhoori,M. Schiavo,Luigi Mariani,Tiziana Camerini,Sasan Roayaie,Myron Schwartz,Gian Luca Grazi,René Adam,Peter Neuhaus,Mauro Salizzoni,Jordi Bruix,Alejandro Forner,Luciano De Carlis,Umberto Cillo,Andrew K. Burroughs,Roberto Troisi,Massimo Rossi,Giorgio Enrico Gerunda,Jan Lerut,Jacques Belghiti,Ilka de Fátima Santana Ferreira Boin,Jean Gugenheim,Fedja Rochling,Bart van Hoek,Pietro Majno +27 more
TL;DR: More patients with hepatocellular carcinoma could be candidates for transplantation if the current dual approach to candidacy, based on the strict Milan criteria, were replaced with a more precise estimation of survival contouring individual tumour characteristics and use of the up-to-seven criteria.
Related Papers (5)
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet,Sergio Ricci,Vincenzo Mazzaferro,Philip Hilgard,Edward Gane,Jean-Frédéric Blanc,André Cosme de Oliveira,Armando Santoro,Jean-Luc Raoul,Alejandro Forner,Myron Schwartz,Camillo Porta,Stefan Zeuzem,Luigi Bolondi,Tim F. Greten,Peter R. Galle,Jean Francois Seitz,Ivan Borbath,Dieter Häussinger,Tom Giannaris,Minghua Shan,M. Moscovici,D. Voliotis,Jordi Bruix +23 more